Primary Immunodeficiency — B Cell Disorders

B cell immunodeficiencies represent a spectrum of disorders characterized by defective B lymphocyte development, maturation, or function, resulting in impaired antibody production and humoral immunity. These conditions, collectively affecting approximately 1 in 1,200 to 1 in 2,000 individuals (though prevalence varies by specific disorder), constitute the largest category of primary immunodeficiencies and are among the most commonly tested immunodeficiency disorders on USMLE examinations. Clinical presentations range from asymptomatic hypogammaglobulinemia detected incidentally to severe, life-threatening recurrent infections beginning in infancy. The clinical significance lies in the high morbidity and mortality risk if unrecognized, coupled with the dramatic response to appropriate immunoglobulin replacement therapy. Understanding the pathophysiology, diagnostic approach, and management of B cell disorders is essential for any practicing clinician, particularly given the expanding recognition of atypical presentations and the increasing prevalence of common variable immunodeficiency (CVID) in adult populations.

B cell immunodeficiencies arise from disruptions at critical developmental and functional stages of B lymphocyte biology, each producing distinct clinical phenotypes:

- B Cell Development and Maturation Defects: B lymphocytes develop in the bone marrow through sequential stages beginning with hematopoietic stem cells differentiating into common lymphoid progenitors, then pro-B cells, pre-B cells, and immature B cells. This process requires intact signaling through the pre-B cell receptor (pre-BCR) complex and B cell receptor (BCR), involving critical proteins including RAG1/RAG2 (recombination-activating genes responsible for V(D)J recombination), BTK (Bruton tyrosine kinase), μ heavy chain, λ5, and surrogate light chains. Defects in any component of this pathway impair B cell receptor gene rearrangement or signal transduction, preventing productive B cell development. For example, X-linked agammaglobulinemia (XLA) results from BTK mutations, blocking the transition from pre-B cells to mature B cells, leaving patients with <1% circulating B cells and virtually absent immunoglobulin. Similarly, defects in RAG genes produce Omenn syndrome or adenosine deaminase (ADA) deficiency, wherein accumulated toxic metabolites preferentially damage lymphoid tissue. These maturation defects result in hypogammaglobulinemia or near-total absence of serum immunoglobulin across all classes and subclasses.

- Germinal Center and Class Switch Recombination (CSR) Defects: After antigen encounter in secondary lymphoid tissues, activated B cells undergo class switch recombination—a process converting IgM-secreting B cells to IgG, IgA, or IgE-secreting cells. This process requires activation-induced cytidine deaminase (AID), which deaminates cytosine to uracil in DNA within switch regions upstream of constant region exons. Mutations in AID or downstream signaling components (such as CD40, CD40 ligand in hyper-IgM syndrome, or NEMO in ectodermal dysplasia with immunodeficiency) impair CSR while leaving IgM production intact or elevated. These disorders produce the characteristic pattern of markedly elevated IgM with profound deficiency of IgG and IgA, distinguishing them from maturation defects. Furthermore, these same patients often show defective somatic hypermutation, resulting in low-affinity antibodies that fail to protect adequately against infection despite high immunoglobulin levels.

- Antibody Production and Plasma Cell Differentiation Defects: Some B cell disorders involve intact B cell development and differentiation but impaired terminal differentiation into antibody-secreting plasma cells or defects in isotype-specific antibody generation. Common variable immunodeficiency (CVID) exemplifies this heterogeneous group, involving mutations in genes required for B cell activation (such as ICOS, CD81, BAFF-R), germinal center reactions, or plasma cell survival (such as TACI mutations). Patients typically present with normal numbers of circulating B cells but defective germinal center formation, abnormal B cell subset distribution (lacking switched memory B cells in some cases, or with expanded marginal zone B cells in others), or impaired response to vaccination. The result is hypogammaglobulinemia affecting multiple immunoglobulin classes, though IgM may be relatively preserved. Additionally, some patients with CVID develop specific antibody deficiency (SAD), wherein total immunoglobulin levels remain in the low-normal range but antibodies to specific pathogens (notably polysaccharides) are profoundly deficient, explaining recurrent sinopulmonary infections despite seemingly adequate total immunoglobulin.

- Immunoglobulin Subclass Deficiency: Selective deficiency of IgG subclasses (particularly IgG2 and IgG3) or IgA without reduction in total IgG can result from CSR defects affecting specific constant regions or developmental checkpoints affecting particular B cell lineages. IgA deficiency, the most common primary immunodeficiency (affecting 1 in 300 to 1 in 3,000 individuals depending on ethnicity), reflects impaired CSR to IgA or IgA+ B cell loss through unknown mechanisms involving environmental and genetic factors. While most individuals with IgA deficiency remain asymptomatic, a subset develops selective IgA deficiency with recurrent sinopulmonary infections, and critically, approximately 20-50% develop anti-IgA antibodies that cause anaphylaxis upon exposure to blood products containing IgA (transfusion reactions or intravenous immunoglobulin containing trace IgA). IgG subclass deficiencies produce variable phenotypes depending on which subclasses are affected: IgG1 deficiency typically causes severe hypogammaglobulinemia, while isolated IgG4 deficiency may cause mild symptoms, and IgG2/IgG3 deficiency predisposes specifically to infections with encapsulated organisms.

- B Cell Receptor Signaling Defects: Beyond developmental maturation, impaired BCR signal transduction prevents adequate B cell activation, proliferation, and antibody secretion upon antigen encounter. This involves both surface receptor complexes (BCR, CD19, CD21, CD81) and downstream tyrosine kinases (Syk, BTK, Blnk). Even with normal B cell numbers, signaling defects prevent appropriate responses to T cell-independent and T cell-dependent antigens, resulting in functional immunodeficiency despite quantitatively adequate B cells.

- X-Linked Agammaglobulinemia (XLA) and BTK Mutations: XLA accounts for approximately 80-85% of agammaglobulinemia cases and results from loss-of-function mutations in the BTK gene located at Xq22. BTK is a tyrosine kinase essential for pre-BCR and BCR signal transduction; mutations prevent B cell development beyond the pro-B to pre-B transition, resulting in virtually absent mature B cells (<1%) and severe hypogammaglobulinemia (IgG typically <100 mg/dL). The X-linked inheritance pattern means affected males present in infancy with recurrent pyogenic infections (Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, gram-negative organisms) beginning around 3-6 months of age as maternal antibodies wane. Female carriers are asymptomatic due to X-inactivation.

- Autosomal Recessive Agammaglobulinemia: Non-BTK mutations account for 15-20% of agammaglobulinemia cases and involve genes encoding other components of pre-BCR or BCR signaling (μ heavy chain, λ5, Ig-α/Ig-β, BLNK, Syk) or V(D)J recombination machinery (RAG1, RAG2). These autosomal recessive conditions present similarly to XLA but with no sex predilection and variable severity depending on residual protein function.

- Adenosine Deaminase (ADA) Deficiency and Nucleoside Phosphorylase (PNP) Deficiency: These autosomal recessive metabolic disorders disrupt purine metabolism, causing accumulation of toxic metabolites (particularly 2'-deoxyadenosine in ADA deficiency) that are preferentially toxic to lymphoid tissue. While these primarily affect T cells (causing severe combined immunodeficiency in 85% of ADA deficiency cases), approximately 15% present with selective B cell deficiency or combined immunodeficiency. ADA deficiency causes impaired B cell development and increased B cell apoptosis; patients typically present with failure to thrive, recurrent infections of both bacterial and opportunistic types, and hepatosplenomegaly.

- Hyper-IgM Syndromes (HIGM): These disorders disrupt class switch recombination while preserving or increasing IgM production. HIGM Type 1 (X-linked, most common form, 70% of HIGM cases) results from CD40 ligand (CD40L) mutations on T cells. CD40L-CD40 interaction is essential for T cell help to B cells; its absence prevents normal germinal center formation, somatic hypermutation, and class switching. Patients have normal or elevated IgM but profound deficiency of IgG, IgA, and IgE. HIGM Type 2 (autosomal recessive) involves AID mutations preventing activation-induced cytidine deaminase activity necessary for both CSR and somatic hypermutation. HIGM Type 3 involves CD40 mutations, and HIGM Types 4-6 involve other CSR-related proteins (UNG, PMS2, NEMO). Patients characteristically present with recurrent sinopulmonary infections (from IgG deficiency) and opportunistic infections including Pneumocystis jirovecii pneumonia (from T cell dysfunction, particularly in HIGM-1), chronic diarrhea, hepatomegaly from granulomatous inflammation, and in HIGM-1, increased risk of lymphoid malignancies.

- Common Variable Immunodeficiency (CVID): CVID represents the most common symptomatic primary immunodeficiency (incidence 1 in 10,000 to 1 in 50,000) and is genetically and immunologically heterogeneous. Approximately 10-15% of patients have identifiable monogenic mutations in genes affecting B cell development, activation, or plasma cell survival (ICOS, CD81, BAFF-R/TNFRSF13C, TACI/TNFRSF13B, CD19, CD20, CD21, PIK3CD, PIK3R1, PMS2, NFKB1, NFKB2, RELA), while 85-90% have polygenic inheritance or unclear etiology. Presentation typically occurs in early adulthood (though can range from childhood to late adulthood), with highly variable immunologic findings reflecting multiple pathogenic mechanisms: some patients have reduced B cells (with defects in B cell survival), others have normal or increased B cell numbers but impaired differentiation into antibody-secreting cells, and still others have selective deficiencies of particular B cell subsets (such as absent switched memory B cells or expanded marginal zone B cells). CVID patients have recurrent sinopulmonary infections, gastrointestinal infections, and significantly increased risks of autoimmunity (25-70% develop autoimmune cytopenias, enteropathy, or systemic autoimmunity), lymphoid malignancies (60-fold increased risk of lymphoma), and granulomatous inflammation.

- Selective IgA Deficiency: The most common primary immunodeficiency (1 in 300 in European populations, 1 in 3,000 in East Asian populations), selective IgA deficiency involves serum IgA <7 mg/dL with normal total IgG and IgM. Etiology remains incompletely understood but involves both genetic factors (associated with HLA-A1, -B8, -DR3 haplotype) and possible environmental triggers (infections, medications including anticonvulsants and sulfonamides, possibly celiac disease). While most patients remain asymptomatic, approximately 50% develop recurrent sinopulmonary or gastrointestinal infections (from loss of mucosal immunity without compensatory IgG), and 20-50% develop anti-IgA antibodies that cause severe transfusion reactions or anaphylaxis upon exposure to exogenous IgA.

- IgG Subclass Deficiency: Selective deficiencies of IgG1, IgG2, IgG3, or IgG4 can occur with normal total IgG. IgG2 deficiency is clinically most significant, as IgG2 provides primary immunity to polysaccharide antigens (pneumococcal capsule, meningococcal polysaccharide); patients with IgG2 deficiency have recurrent infections with encapsulated organisms despite adequate total IgG and normal responses to protein antigens. IgG3 deficiency is associated with recurrent respiratory infections. IgG4 deficiency is usually asymptomatic. IgG1 deficiency (rare) causes severe hypogammaglobulinemia and resembles XLA. Genetics involve CSR defects or selective B cell subset loss; environmental factors may contribute.

- Specific Antibody Deficiency (SAD): Some patients with recurrent infections have normal or near-normal total immunoglobulin levels but markedly deficient antibodies to specific pathogens, particularly polysaccharide antigens (pneumococcal, meningococcal). This can occur as primary SAD (isolated genetic defect in response to polysaccharide antigens) or secondary to other immunodeficiencies. SAD indicates functional B cell defects despite quantitatively adequate immunoglobulin.

- Transient Hypogammaglobulinemia of Infancy (THI): A benign condition affecting 1-2% of infants, characterized by prolonged physiologic hypogammaglobulinemia where the normal postnatal decline in maternal IgG and delay in infant IgG synthesis result in low levels (typically 300-500 mg/dL) persisting beyond 3-4 months. Affected infants may experience increased infections during this window but spontaneously normalize by 3-6 years. THI is distinguished from pathologic hypogammaglobulinemia by ultimately normal immunoglobulin levels and normal B cell development.

- Recurrent Sinopulmonary Infections: The hallmark presentation of B cell immunodeficiency involves recurrent bacterial respiratory tract infections, including otitis media, sinusitis, bronchitis, and pneumonia. These infections are classically caused by encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae type b, Neisseria meningitidis, Streptococcus agalactiae) that require opsonizing antibodies for effective complement activation and phagocytosis. In untreated XLA, patients may experience 4-5 episodes of pneumonia annually or more; in CVID, sinopulmonary disease develops insidiously over years. The pathophysiology reflects absent or inadequate specific antibodies preventing opsonization and consequent impaired clearance by alveolar macrophages and polymorphonuclear leukocytes.

- Gastrointestinal Infections and Enteropathy: Recurrent or chronic diarrhea and gastrointestinal infections represent prominent features of B cell immunodeficiency, particularly involving Giardia lamblia, Cryptosporidium, Campylobacter, Salmonella, and other enteric pathogens. IgA deficiency is particularly predisposing, as IgA represents the primary mucosal antibody; patients lose both immune exclusion (preventing pathogen adherence to epithelial cells) and immune neutralization of toxins. In CVID, approximately 10-20% develop nodular lymphoid hyperplasia (visible nodules of lymphoid tissue in small bowel mucosa on endoscopy), which may be asymptomatic or associated with protein-losing enteropathy, malabsorption, or even intestinal obstruction. Some CVID patients develop inflammatory bowel disease-like enteropathy. Chronic diarrhea in untreated immunodeficiency can lead to nutritional deficiencies, failure to thrive in children, and wasting in adults.

- Systemic/Disseminated Infections: In severe immunodeficiencies like XLA, patients are at risk for fulminant bacteremia, meningitis, and sepsis. Notably, despite adequate T cell function, they remain highly susceptible to echovirus, coxsackievirus, and other enteroviruses, which cause chronic or recurrent meningoencephalitis, often termed progressive enteroviral encephalomyelitis. This propensity for chronic enteroviral infection is pathognomonic for antibody deficiency and is rarely seen in other immunodeficiencies.

- Age of Presentation and Symptom Timeline: In XLA, infections typically begin